150 related articles for article (PubMed ID: 29749539)
21. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
[TBL] [Abstract][Full Text] [Related]
22. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
23. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation.
Dent J; Hall GD; Wilkinson N; Perren TJ; Richmond I; Markham AF; Murphy H; Bell SM
Br J Cancer; 2003 May; 88(10):1578-83. PubMed ID: 12771925
[TBL] [Abstract][Full Text] [Related]
24. Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.
Katagiri H; Nakayama K; Razia S; Nakamura K; Sato E; Ishibashi T; Ishikawa M; Iida K; Ishikawa N; Otsuki Y; Nakayama S; Kyo S
Int J Oncol; 2015 Dec; 47(6):2037-44. PubMed ID: 26458502
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
27. Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.
Okamoto A; Sehouli J; Yanaihara N; Hirata Y; Braicu I; Kim BG; Takakura S; Saito M; Yanagida S; Takenaka M; Yamaguchi N; Morikawa A; Tanabe H; Yamada K; Yoshihara K; Enomoto T; Itamochi H; Kigawa J; Matsumura N; Konishi I; Aida S; Aoki Y; Ishii N; Ochiai K; Akiyama T; Urashima M
PLoS One; 2015; 10(2):e0116977. PubMed ID: 25658832
[TBL] [Abstract][Full Text] [Related]
28. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
[TBL] [Abstract][Full Text] [Related]
29. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.
Wang H; Tan M; Zhang S; Li X; Gao J; Zhang D; Hao Y; Gao S; Liu J; Lin B
Int J Mol Sci; 2015 Feb; 16(2):3391-404. PubMed ID: 25658794
[TBL] [Abstract][Full Text] [Related]
30. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
Diaz ES; Walts AE; Karlan BY; Walsh CS
Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
[TBL] [Abstract][Full Text] [Related]
31. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
32. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
[TBL] [Abstract][Full Text] [Related]
33. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas.
Suehiro Y; Sakamoto M; Umayahara K; Iwabuchi H; Sakamoto H; Tanaka N; Takeshima N; Yamauchi K; Hasumi K; Akiya T; Sakunaga H; Muroya T; Numa F; Kato H; Tenjin Y; Sugishita T
Oncology; 2000 Jun; 59(1):50-6. PubMed ID: 10895067
[TBL] [Abstract][Full Text] [Related]
34. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
Iramaneerat K; Rattanatunyong P; Khemapech N; Triratanachat S; Mutirangura A
Int J Gynecol Cancer; 2011 Jan; 21(1):51-7. PubMed ID: 21330831
[TBL] [Abstract][Full Text] [Related]
35. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Hirasawa A; Saito-Ohara F; Inoue J; Aoki D; Susumu N; Yokoyama T; Nozawa S; Inazawa J; Imoto I
Clin Cancer Res; 2003 Jun; 9(6):1995-2004. PubMed ID: 12796361
[TBL] [Abstract][Full Text] [Related]
36. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
Tan DS; Iravani M; McCluggage WG; Lambros MB; Milanezi F; Mackay A; Gourley C; Geyer FC; Vatcheva R; Millar J; Thomas K; Natrajan R; Savage K; Fenwick K; Williams A; Jameson C; El-Bahrawy M; Gore ME; Gabra H; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2011 Mar; 17(6):1521-34. PubMed ID: 21411445
[TBL] [Abstract][Full Text] [Related]
37. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.
Letessier A; Sircoulomb F; Ginestier C; Cervera N; Monville F; Gelsi-Boyer V; Esterni B; Geneix J; Finetti P; Zemmour C; Viens P; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Chaffanet M
BMC Cancer; 2006 Oct; 6():245. PubMed ID: 17040570
[TBL] [Abstract][Full Text] [Related]
38. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
[TBL] [Abstract][Full Text] [Related]
39. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma.
Zhang H; Lu J; Lu Y; Zhou J; Wang Z; Liu H; Xu C
PLoS One; 2017; 12(5):e0177520. PubMed ID: 28498842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
